Payment overview · 2025
General Payments
$171.37
8 reported records · 8 companies
Healthcare provider profile · identity verified
Charles Wesley Power, MD
Allopathic & Osteopathic Physicians|Family Medicine · POULSBO, WA · NPI 1578639480
Verified facts
What the public records show
CMS Open Payments records show Charles Wesley Power, MD received $171.37 in general payments during 2025 across 8 reported records.
Aimmune Therapeutics, Inc. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.20 | 18.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.16 | 14.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.78 | 13.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.16 | 12.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $18.44 | 10.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.50 | 10.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.85 | 9.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.28 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $171.37 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 276 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 65 |
| Gabapentin | Gabapentin | 231 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 202 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 181 | 50 |
| Tramadol Hcl | Tramadol Hcl | 168 | 41 |
| Irbesartan | Irbesartan | 152 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 35 |
| Metformin Hcl | Metformin Hcl | 146 | 33 |
| Lisinopril | Lisinopril | 145 | 39 |
| Telmisartan | Telmisartan | 140 | 34 |
| Carvedilol | Carvedilol | 131 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 36 |
| Alprazolam | Alprazolam | 120 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 32 |
| Liothyronine Sodium | Liothyronine Sodium | 118 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 26 |
| Bupropion Xl | Bupropion Hcl | 106 | 19 |
| Potassium Chloride | Potassium Chloride | 105 | 26 |
| Trazodone Hcl | Trazodone Hcl | 103 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 28 |
| Montelukast Sodium | Montelukast Sodium | 97 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 27 |
| Meloxicam | Meloxicam | 91 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 24 |
| Simvastatin | Simvastatin | 90 | 25 |
| Diazepam | Diazepam | 88 | 16 |
| Allopurinol | Allopurinol | 87 | 23 |
| Lorazepam | Lorazepam | 87 | 21 |
| Clonazepam | Clonazepam | 79 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 27 |
| Furosemide | Furosemide | 73 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 73 | 37 |
| Morphine Sulfate Er | Morphine Sulfate | 72 | suppressed |
| Famotidine | Famotidine | 71 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 12 |
| Methadone Hcl | Methadone Hcl | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 17 |
| Sertraline Hcl | Sertraline Hcl | 63 | 15 |
| Ozempic | Semaglutide | 62 | suppressed |
| Methocarbamol | Methocarbamol | 60 | 11 |
| Eliquis | Apixaban | 58 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 23 |
| Metformin Hcl Er | Metformin Hcl | 55 | 13 |
| Baclofen | Baclofen | 52 | 13 |
| Losartan Potassium | Losartan Potassium | 52 | 17 |
| Pregabalin | Pregabalin | 52 | 11 |
| Jardiance | Empagliflozin | 51 | 12 |
| Eszopiclone | Eszopiclone | 49 | suppressed |
| Omeprazole | Omeprazole | 48 | 14 |
| Azithromycin | Azithromycin | 46 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Prednisone | Prednisone | 46 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 17 |
| Ondansetron Odt | Ondansetron | 44 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Spironolactone | Spironolactone | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Estradiol | Estradiol | 38 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 12 |
| Celecoxib | Celecoxib | 37 | 16 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Topiramate | Topiramate | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Modafinil | Modafinil | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 19 |
| Fentanyl | Fentanyl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 17 |
| Testosterone | Testosterone | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 16 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Sumatriptan | Sumatriptan | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $171.37 · 8 records | Aimmune Therapeutics, Inc. | AREXVY, BREZTRI, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), MOUNJARO, NEXLETOL, NURTEC ODT, SHINGRIX, TRINTELLIX, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error